184 related articles for article (PubMed ID: 17166246)
21. Eptifibatide and 7E3, but not tirofiban, inhibit alpha(v)beta(3) integrin-mediated binding of smooth muscle cells to thrombospondin and prothrombin.
Lele M; Sajid M; Wajih N; Stouffer GA
Circulation; 2001 Jul; 104(5):582-7. PubMed ID: 11479257
[TBL] [Abstract][Full Text] [Related]
22. Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison Of Measurements of Platelet aggregation with Aggrastat, Reopro, and Eptifibatide.
Batchelor WB; Tolleson TR; Huang Y; Larsen RL; Mantell RM; Dillard P; Davidian M; Zhang D; Cantor WJ; Sketch MH; Ohman EM; Zidar JP; Gretler D; DiBattiste PM; Tcheng JE; Califf RM; Harrington RA
Circulation; 2002 Sep; 106(12):1470-6. PubMed ID: 12234950
[TBL] [Abstract][Full Text] [Related]
23. Increased ability of tirofiban to maintain its inhibitory effects on the binding of fibrinogen to platelets in blood from patients with and without diabetes mellitus.
Schneider DJ; Keating FK; Baumann PQ; Whitaker DA; Sobel BE
Coron Artery Dis; 2006 Feb; 17(1):57-61. PubMed ID: 16374143
[TBL] [Abstract][Full Text] [Related]
24. Effects of the glycoprotein IIb/IIIa antagonist Roxifiban on P-selectin expression, fibrinogen binding, and microaggregate formation in a phase I dose-finding study: no evidence for platelet activation during treatment with a glycoprotein IIb/IIIa antagonist.
Seiffert D; Thomas BE; Bradley JD; Munzer DA; Tchinnes MA; Kornhauser DM; Cain VA; Hua TA; Feuerstein GZ; Martin DE; Stern AM
Platelets; 2003 May; 14(3):179-87. PubMed ID: 12850842
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of platelet-dependent prothrombinase activity and thrombin generation by glycoprotein IIb/IIIa receptor-directed antagonists: potential contributing mechanism of benefit in acute coronary syndromes.
Li Y; Spencer FA; Ball S; Becker RC
J Thromb Thrombolysis; 2000 Aug; 10(1):69-76. PubMed ID: 10947916
[TBL] [Abstract][Full Text] [Related]
26. Intracoronary eptifibatide bolus administration during percutaneous coronary revascularization for acute coronary syndromes with evaluation of platelet glycoprotein IIb/IIIa receptor occupancy and platelet function: the Intracoronary Eptifibatide (ICE) Trial.
Deibele AJ; Jennings LK; Tcheng JE; Neva C; Earhart AD; Gibson CM
Circulation; 2010 Feb; 121(6):784-91. PubMed ID: 20124127
[TBL] [Abstract][Full Text] [Related]
27. Conformation-Specific Blockade of αIIbβ3 by a Non-RGD Peptide to Inhibit Platelet Activation without Causing Significant Bleeding and Thrombocytopenia.
Shen C; Liu M; Tian H; Li J; Xu R; Mwangi J; Lu Q; Hao X; Lai R
Thromb Haemost; 2020 Oct; 120(10):1432-1441. PubMed ID: 32717755
[TBL] [Abstract][Full Text] [Related]
28. Different effects of various anti-GPIIb-IIIa agents on shear-induced platelet activation and expression of procoagulant activity.
Goto S; Tamura N; Li M; Handa M; Ikeda Y; Handa S; Ruggeri ZM
J Thromb Haemost; 2003 Sep; 1(9):2022-30. PubMed ID: 12941046
[TBL] [Abstract][Full Text] [Related]
29. Regulation of clot retraction by glycoprotein IIb/IIIa antagonists.
Seiffert D; Pedicord DL; Kieras CJ; He B; Stern AM; Billheimer JT
Thromb Res; 2002 Nov; 108(2-3):181-9. PubMed ID: 12590956
[TBL] [Abstract][Full Text] [Related]
30. Tirofiban (Aggrastat) protects platelets and decreases platelet-granulocyte binding in an extracorporeal circulation model.
Straub A; Azevedo R; Beierlein W; Wendel HP; Dietz K; Ziemer G
Thorac Cardiovasc Surg; 2006 Apr; 54(3):162-7. PubMed ID: 16639676
[TBL] [Abstract][Full Text] [Related]
31. Mapping the binding domains of the alpha(IIb) subunit. A study performed on the activated form of the platelet integrin alpha(IIb)beta(3).
Biris N; Abatzis M; Mitsios JV; Sakarellos-Daitsiotis M; Sakarellos C; Tsoukatos D; Tselepis AD; Michalis L; Sideris D; Konidou G; Soteriadou K; Tsikaris V
Eur J Biochem; 2003 Sep; 270(18):3760-7. PubMed ID: 12950259
[TBL] [Abstract][Full Text] [Related]
32. Binding of a fibrinogen mimetic stabilizes integrin alphaIIbbeta3's open conformation.
Hantgan RR; Rocco M; Nagaswami C; Weisel JW
Protein Sci; 2001 Aug; 10(8):1614-26. PubMed ID: 11468358
[TBL] [Abstract][Full Text] [Related]
33. The disintegrin echistatin stabilizes integrin alphaIIbbeta3's open conformation and promotes its oligomerization.
Hantgan RR; Stahle MC; Connor JH; Lyles DS; Horita DA; Rocco M; Nagaswami C; Weisel JW; McLane MA
J Mol Biol; 2004 Oct; 342(5):1625-36. PubMed ID: 15364586
[TBL] [Abstract][Full Text] [Related]
34. Optimal use of platelet glycoprotein IIb/IIIa receptor antagonists in patients undergoing percutaneous coronary interventions.
Starnes HB; Patel AA; Stouffer GA
Drugs; 2011 Oct; 71(15):2009-30. PubMed ID: 21985168
[TBL] [Abstract][Full Text] [Related]
35. The integrin alpha IIb beta 3 contains distinct and interacting binding sites for snake-venom RGD (Arg-Gly-Asp) proteins. Evidence that the receptor-binding characteristics of snake-venom RGD proteins are related to the amino acid environment flanking the sequence RGD.
Rahman S; Lu X; Kakkar VV; Authi KS
Biochem J; 1995 Nov; 312 ( Pt 1)(Pt 1):223-32. PubMed ID: 7492316
[TBL] [Abstract][Full Text] [Related]
36. Comparative efficacy of fibrinogen and platelet supplementation on the in vitro reversibility of competitive glycoprotein IIb/IIIa (alphaIIb/beta3) receptor-directed platelet inhibition.
Li YF; Spencer FA; Becker RC
Am Heart J; 2001 Aug; 142(2):204-10. PubMed ID: 11479455
[TBL] [Abstract][Full Text] [Related]
37. A randomized trial assessing the impact of three different glycoprotein IIb/IIIa antagonists on glycoprotein IIb/IIIa platelet receptor inhibition and clinical endpoints in patients with acute coronary syndromes.
Holmes LE; Gupta R; Rajendran S; Luu J; French JK; Juergens CP
Cardiovasc Ther; 2016 Oct; 34(5):330-6. PubMed ID: 27327862
[TBL] [Abstract][Full Text] [Related]
38. Augmentation of inhibitory effects of glycoprotein IIb-IIIa antagonists in patients with diabetes.
Keating FK; Whitaker DA; Sobel BE; Schneider DJ
Thromb Res; 2004; 113(1):27-34. PubMed ID: 15081562
[TBL] [Abstract][Full Text] [Related]
39. Variable responses to inhibition of fibrinogen binding induced by tirofiban and eptifibatide in blood from healthy subjects.
Holmes MB; Sobel BE; Schneider DJ
Am J Cardiol; 1999 Jul; 84(2):203-7. PubMed ID: 10426341
[TBL] [Abstract][Full Text] [Related]
40. Comparative assessment of platelet GpIIb/IIIa receptor occupancy ratio with Eptifibatide/Tirofiban in patients presenting with ACS and undergoing PCI.
Puri A; Bansal A; Narain VS; Sethi R; Dwivedi SK; Puri VK; Saran RK
Indian Heart J; 2013; 65(2):152-7. PubMed ID: 23647894
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
